Table 5. Clinical outcomes stratified by disease subtype.

Outcome	All (n=22)	MCL (n=13)	LBCL* (n=9)
Time to first response, median, months(range)	2 (1-4)	2(2-4)	2(1-2)
Time to best response,median, months (range)	2 (1-10)	2(2-10)	2(1-3)
Complete remission in response to SCT	22(100%)	13(100%)	9(100%)
Progression-free survival, median, months (range)	23(14-32)	19(10-28)	NR
Overall survival, median, months (range)	44(NR)	24(13-35)	NR

Abbreviations:MCL, mantle cell lymphoma; LBCL,large B-cell lymphoma; DLBCL,diffuse large B-cell lymphoma; FLG3,grade 3 follicular lymphoma;TL,transformed lymphoma; SCT, stem cell transplantation; NR, not reached.

Data represent number of patients (%) unless otherwise specified.

^*LBCL includes DLBCL,FLG3, and TL.